Objectives: Evidence for an association between duration of untreated illness (DUI) with clinical and functional outcome or brain volume (change) in schizophrenia patients is inconclusive. We aimed to investigate the relationship between DUI, outcome and brain volume at illness onset or brain volume change during the first five years of the illness in first-episode patients. Methods: Magnetic resonance images were acquired at baseline (T0) and after 5-year (T5) of 57 schizophrenia patients. Correlations were calculated in patients between brain volume (change), DUI and outcome variables. Results: We found no significant correlation between DUI and brain volume (change) in schizophrenia patients. A longer DUI was significantly correlated with higher PANSS scores at T0 and T5, and with higher scores on the Camberwell Assessment of Need scale at T5. Baseline volume of the cerebrum and lateral ventricles, and cerebellum volume (change) were associated with PANSS scores at T0 and T5. Conclusion: Although clinical outcome is associated with both brain volume (change) and DUI, we found no evidence for a relationship between DUI and brain volume (change). DUI and baseline brain volume or 5-year brain volume (change) seem to explain different parts of the variation in clinical outcome.
Introduction
Schizophrenia is, in the majority of cases, characterized by an insidious onset, often preceded by a decline in functioning. Duration of untreated psychosis (DUP), prodrome (DPD) and untreated illness (DUI) have all been used to characterize the period before the start of treatment or the onset of psychosis. DUP is the time between onset of psychosis and the start of treatment, which is generally defined as hospitalization (Madsen et al., 1999; Perkins et al., 2005; Bangalore et al., 2009) or (adequate) antipsychotic treatment (Perkins et al., 2005; Crespo-Facorro et al., 2007a; Selten et al., 2007; Emsley et al., 2008; Crumlish et al., 2009) . Onset of psychosis is usually determined retrospectively and is defined as the onset of first psychotic symptoms (Perkins et al., 2005; Lappin et al., 2006; Crespo-Facorro et al., 2007a; Selten et al., 2007; Emsley et al., 2008; Bangalore et al., 2009) .
The start of DPD is usually defined as a persistent deviation from the individual's normal premorbid functioning, behavior or personality and/or the emergence of prodromal psychiatric symptoms that do not fulfill the criteria for psychosis (Loebel et al., 1992; Crespo-Facorro et al., 2007a; Bangalore et al., 2009; Crumlish et al., 2009; Ebdrup et al., 2010; O'Callaghan et al., 2010) . It ends at the emergence of psychotic symptoms. Finally, DUI is defined as the sum of DUP and DPD.
Clinical and social outcome variables have been associated with DUI (Loebel et al., 1992; Crumlish et al., 2009; Owens et al., 2010) and DPD (Malla et al., 2002; Harrigan et al., 2003; Fusar-Poli et al., 2009 ) in that longer DUI or DPD correlated with poorer outcome. However, others could not replicate such a relationship (Barnes et al., 2000; Craig et al., 2000; Ho et al., 2000; Hoff et al., 2000; Norman et al., 2001; Malla et al., 2002; Harrigan et al., 2003; Selten et al., 2007; Gonzalez-Blanch et al., 2008) . A small to moderate effect of DUP on outcome in schizophrenia, including symptom remission and functional rehabilitation has been established in two reviews (Marshall et al., 2005; Perkins et al., 2005) .
Interestingly, poorer outcome has also been associated with smaller brain volumes (Buchsbaum et al., 2003; Molina et al., 2010 ), larger ventricles (DeLisi et al., 2004 and excessive brain volume loss over time (Cahn et al., 2002; Cahn et al., 2006; Van Haren et al., 2008) , for review see Kempton et al., 2010) . Therefore, we hypothesize that DUP, DUI or DPD through their effect on outcome, are associated with (change in) brain volume abnormalities in schizophrenia patients or vice versa. Consequently, a longer delay of treatment would be related to larger decline of brain volume. Indeed, cross-sectional studies provide evidence for an association between brain abnormalities and a longer DUP, DUI or DPD (Angelopoulos et al., 2002; Bangalore et al., 2009; Crespo-Facorro et al., 2007a,b; Ho et al., 2003; Keshavan et al., 1998; Lappin et al., 2006; Madsen et al., 1999; Penttila et al., 2010; Takahashi et al., 2007; Théberge et al., 2004) . So far, only one longitudinal study investigated the relationship between DUP, outcome and global brain volume change over time using computed tomography (CT), and found no evidence for such a relationship (Madsen et al., 1999) . The advantage of longitudinal studies is that repeated observation in the same individual are obtained and these may have more power than observations from cross-sectional studies do.
The present study aimed to investigate the relationship between DUI, global brain volume (change), and outcome in first-episode schizophrenia patients.
Materials and methods

Subjects and design
Patients, aged 17-40 years, with a maximum antipsychotics exposure of 6 months, were recruited from The First Episode Schizophrenia Research Program at the University Medical Center, Utrecht, The Netherlands. After complete description of the study written informed consent was obtained from all participants. The Medical Ethics Review Board of the University Medical Centre Utrecht approved the study. This study was performed in accordance with the Declaration of Helsinki. Patients who had an MRI scan at inclusion (T0) and who were diagnosed according to DSM-IV criteria with schizophrenia at follow-up (T5) were included. Diagnosis was assessed with the Comprehensive Assessment of Symptoms and History Schizophrenia (Andreasen et al., 1992) . The Positive and Negative Syndrome Scale (PANSS) was performed at T0 and T5 (Kay et al., 1987 (Kay et al., , 1988 . At T5 both the Global Assessment of Functioning (GAF) and the Camberwell Assessment of Need (CAN) were performed (Endicott et al., 1976; Goldman et al., 1992; Phelan et al., 1995) . Course of illness data to determine DUI was collected retrospectively using patient reports prompted by key data and data from a shortened version of the Interview for the Retrospective Assessment of the Onset of schizophrenia (IRAOS) at T5 (Hafner et al., 1992) . Furthermore, a careful examination of the medical records was carried out and the treating psychiatrist and/or key worker were interviewed.
The duration of untreated illness (DUI) was defined as the period from onset of prodrome to the start of antipsychotic treatment. Criterion B from the DSM-III was used to define onset of prodrome (when one or more major areas of functioning such as work, interpersonal relations, or self care are markedly below the level achieved prior to the onset). Consensus was reached between two independent researchers (WC and TCM) about the date the prodrome started.
To calculate the lifetime cumulative dosage of antipsychotic medication up to T0 and T5, a careful examination of the medical records was carried out. A table from the Dutch National Health Service was used to derive the haloperidol equivalents for typical antipsychotics (No authors listed, 2007) (conversion rates: broomperidol 1:1, droperidol 1:1, haloperidol 1:1, penfluridol 1:1, perfenazine 5:1, pimozide 0.85:1, pipamperon 50:1, zuclopentixol 5:1). For atypical antipsychotic medication, the respective pharmaceutical companies suggested conversion rates into haloperidol equivalents (H-EQ) (clozapine, 40:1; olanzapine, 2.5:1; quetiapine, 50:1; risperidone, 1:1; sulpiride, 170:1).
In addition, 56 controls were included, group-matched for age, gender and handedness, in order to assess whether this patient sample shows the expected brain abnormalities (i.e., smaller cerebral (gray matter) volume at baseline, and excessive gray matter volume loss over time in patients relative to controls).
MRI data acquisition
Magnetic resonance images (MRIs) were acquired using a 1.5 Tesla Philips NT scanner. Volume measures of the intracranium, total brain (TB), cerebral gray (GM) and white matter (WM), cerebellum (CB), third (V3) and lateral ventricles (LV) were determined. Acquisition parameters and processing have been described previously (Schnack et al., 2001a,b; Van Haren et al., 2003) All segmentations were checked and corrected manually if necessary. The interrater reliabilities of the volume measurements, determined by the ICC were 0.95 and higher.
Data-analysis
Data were checked with the Pearson's Chi-Square test for nominal variables, ANOVA for normally distributed, and Mann-Whitney U test for abnormally distributed continuous variables (Table 1 ). Brain volume (change) was corrected for IC, age and gender using multiple regression analyses. Unstandardized residuals were saved and used in the main analysis. The difference in volume (change) between patients and controls was tested using ANOVA for normally distributed, and MannWhitney U test for abnormally distributed volume variables. Pearson's correlation coefficients, or Spearman Rank correlation coefficients in not-normally distributed variables, were calculated to investigate the association between 1) DUI and corrected brain volume (change) 2) clinical outcome measures (PANSS total and subscores at T0 and T5, GAF and CAN professional total score at T5) and DUI, and 3) clinical outcome measures and corrected brain volume (change). The significant associations were corrected for intake of alcohol or drugs in the three months prior to the study with partial correlations.
At baseline, 36 patients were medication-naïve and correlation analyses on baseline measures of outcome, brain volume and DUI were performed in this subgroup to exclude the influence of medication effects.
SPSS18 was used for all analyses. Only findings with p b 0.01 are presented.
Results
Brain volume (change) in patients and controls
At baseline V3 was larger in patients compared to controls. Patients, compared to controls, showed a more pronounced loss of GM over a five year interval (Table 1) .
DUI and brain volume (change)
No significant correlations were found between brain volume (change) and DUI (Table 2) .
DUI and clinical outcome
Significant associations were found between DUI and clinical and functional outcome, indicating larger DUI to be related to poorer outcome (Table 2, Fig. 1 ). Longer DUI was significantly correlated with higher PANSS total scores at T5 (ρ =.42, p = .003), PANSS positive score at T0 and T5 (T0: ρ = .37, p = .008, T5: ρ =.53, p = .00009) and the PANSS general score at T5 (ρ =.37, p = .01). Furthermore, there was a positive correlation between DUI and the CAN total score at T5 (ρ = .41, p =.004).
Brain volume (change) and clinical outcome
Significant correlations were found between brain volume (change) and level of symptoms at baseline and follow-up measurement (Table 2 ). There was a negative correlation between baseline TB and the negative PANSS score at T0 and T5 (T0: r = −.44, p = .002; T5: ρ = −.40, p = .005). CB change was negatively correlated with the PANSS general score at T0 (r = −.43, p = .01). These correlations suggest that the presence of more symptoms is related to more CSF and less brain tissue. In contrast, positive PANSS score at T5 was negatively correlated to baseline LV (r = −.34, p = .009) and positively to CB (r= .36, p =.01).
After correction for alcohol or drugs intake the study the findings remained the same.
Medication naïve patients
Medication naïve patients (n = 36) showed no significant correlations between baseline brain volume and DUI or outcome.
In medication-naïve patients DUI was significantly longer in patients with a higher baseline PANSS general score (ρ = .49, p = .01).
Discussion
We investigated the association between duration of untreated illness (DUI), brain volume (change), and clinical outcome in firstepisode schizophrenia patients. Our main finding was the lack of association between DUI and brain volume at illness onset or brain volume change during the first five years of illness. We did identify Table 1 Baseline characteristics for all patients, and those patients with both a baseline and a 5-year follow-up scan, as well as for all controls and those controls with both a baseline and a 5-year follow-up scan. Mean baseline brain volumes and mean 5-year change in brain volume in patients and controls. correlations of symptom scores at illness onset and after 5-year followup with both DUI and brain volume (change). It seems that DUI and brain volume explain different parts of the variance in clinical outcome in first-episode schizophrenia patients. Based on our findings one might argue that attempts to shorten DUI will not result in diminished progressive brain volume decreases in patients with schizophrenia, though it might improve clinical outcome.
DUI and brain volume (change)
Our finding is in line with the only longitudinal (CT) study that found no relationship between DUP and 5-year change in frontal brain atrophy in 24 first-episode schizophrenia patients (Madsen et al., 1999) . Two cross-sectional MRI studies, using either a volumetric or a voxel-based morphometry (VBM) approach showed associations between longer DUI and decreased volume or gray matter density in small cortical areas in first-episode schizophrenia patients, i.e., superior temporal gyrus, fusiform gyrus, lingual and parahippocampal gyrus (Keshavan et al., 1998; Bangalore et al., 2009 ). However, other cross-sectional studies found no associations between DUI and brain volume of the thalamus, caudate nucleus, hippocampus, (lateral) ventricles, temporal lobe and cerebral hemispheric volumes (Hoff et al., 2000; Crespo-Facorro et al., 2007a,b; Ebdrup et al., 2010) . Thus, if there is a relation between DUI and brain volume (change), it might be restricted to focal areas of the brain.
Finding no association between DUI and brain volume loss in the first five years of the illness might be confounded by the start of antipsychotic medication. Patients received different kinds of antipsychotics and it is known that types of antipsychotic medication might have either a decrease or increase in brain volumes over time (Ho et al., 2011; Van Haren et al., in press ). Evidence so far suggests that antipsychotics cannot explain all of the brain volume abnormalities in patients (Navari and Dazzan, 2009; Moncrieff and Leo, 2010) .
DUI and clinical outcome
The association between DUP, DUI and DPD and the course of schizophrenia is well established (Marshall et al., 2005; Perkins et al., 2005) , amongst others in studies with a follow-up of 5 year or more (Bottlender et al., 2002; De Haan et al., 2003; Gunduz-Bruce et al., 2005; Harris et al., 2005; Crumlish et al., 2009; White et al., 2009) . Consistent with this, we found DUI to be longer in the presence of poor functional and symptomatic outcome both at baseline and at follow-up measurement. Most convincing was the association between DUI and positive symptoms.
Clarke showed that longer DUI predicted more severe PANSS positive symptoms at 4-year follow-up in first-episode schizophrenia patients (Clarke et al., 2006) . However, other studies failed to find a correlation between positive symptom scores and DUI in first-episode schizophrenia (Barnes et al., 2000; Ho et al., 2000; Barnes et al., 2008; Gonzalez-Blanch et al., 2008) .
At follow-up, the GAF score and DUI were not correlated. This is interesting as several studies suggested such a correlation, with intervals ranging from one to four years (Keshavan et al., 2003; Cahn et al., 2006; Clarke et al., 2006; Fusar-Poli et al., 2009) . These studies investigated patients that were on medication, which obviously affects the symptom levels. Importantly, we included 36 medication naïve patients in whom correlations between symptomatic and functional outcome at baseline and DUI were in the same direction and of similar (or larger) magnitude compared to the total sample. However, due to the smaller size of this sample not all reached significance. In summary, we replicated the associations between DUI and psychiatric symptomatology at baseline, and after five years in medicated as well as medication-naïve patients.
Brain volume (change) and outcome
Showing more positive symptoms at follow-up was related to a smaller lateral ventricle and larger cerebellum at baseline. These correlations seem counterintuitive. One would expect smaller volumes or more pronounced loss to be associated with more severe symptoms Kempton et al., 2010) . Effects in this direction have indeed been shown previously in the cerebellum (Wassink et al., 1999; Premkumar et al., 2009 ). However, we are not the first to find larger cerebellar volumes to be related to poorer outcome (Levitt et al., 1999; Yoshihara et al., 2008) . It is important to note though that there is a long delay between the measurement of the volumes (T0) and the symptom level (T5). As the PANSS scores symptom levels based on the previous week these associations might not be reliable.
We also showed that lower total brain volume was associated with more negative symptoms both at illness onset as well as at follow-up measurement which is in line with earlier studies from our group including overlapping samples (Cahn et al., 2002 (Cahn et al., , 2006 Van Haren et al., 2008) . These findings also corroborate with findings in antipsychoticnaïve first-episode patients that showed reduced temporal and frontal baseline volumes to be associated with less improvement of negative symptoms over 30 months (Gur et al., 1998) , while (progressive) gray matter deficits identified in a VBM study in chronic schizophrenia patients were found to be associated with negative symptoms (Mathalon et al., 2001) . One other first-episode study found the volume of focal areas (with VBM) to be inversely related to the GAF score (Mané et al., 2009 ). However, other research by our group did not identify associations between baseline volume and outcome at follow-up (Van Haren et al., 2003) .
In medication-naïve patients we found equally large correlations, although not significant because of the smaller number of patients, between PANSS total and negative score and baseline TB and third ventricle volume.
Strengths and limitations
We included patients aged 17 to 40 of whom 12 were aged 30 or more at inclusion. Developing schizophrenia after 30 years of age is uncommon, it can be that patients are ill for a long time before being introduced to mental health care. This seems to have been the case since there was a long DUI in these older patients compared to the rest of the patient group, namely 11.6 years (standard deviation (sd) 5.3) versus 3.9 (sd 3.8) years.
Unfortunately, the IRAOS, which aims to measure the onset of schizophrenia was only completed at follow-up measurement. This increases the possibility of inaccurate data due to memory bias. It is difficult to determine DUI, DUP or DPD prospectively, since prediction of psychosis and prodrome is not yet feasible in clinical practice (Cannon et al., 2008) . Furthermore, problems related to memory exist in studies investigating DUI, DUP and DPD (Guay, 1982; Coughlin, 1990; Aleman et al., 1999; Croyle et al., 2006) . To ensure internal validity we obtained consensus between two investigators about the time of onset of prodrome.
An important confounder is level of premorbid functioning. DUI was defined as the period from onset of prodrome to the start of antipsychotic treatment. Onset of prodrome was defined as a decline in functioning in one or more major areas (e.g., work, interpersonal relations, self care), markedly below the level achieved prior to the onset. What we looked for was a relatively sudden and clear decline in the level of functioning. Whether individuals were high or low functioning at the time of this change was not relevant. In that sense, level of premorbid functioning is unrelated to DUI. However, there might still be an association. As we did not obtain information on premorbid functioning we cannot exclude this possibility.
The mean DUI determined in our study (313.4 weeks), is higher than previously reported DUIs that vary from 119 to 227 weeks (Robinson et al., 1999; Malla et al., 2006) . This might be a consequence of the large variation in defining onset of illness, which differs from "first behavioral changes related to the illness" (Rabiner et al., 1986; Loebel et al., 1992; Harrison et al., 1999; Robinson et al., 1999) or "first personality and behavioral changes (Barnes et al., 2000) " to "first non-specific (psychiatric) symptom related to psychosis" (Malla et al., 2002; Gonzalez-Blanch et al., 2008) or a combination of these (Keshavan et al., 2003; Clarke et al., 2006; Fusar-Poli et al., 2009; O'Callaghan et al., 2010) . The definition we used is well described and has been used before (Selten et al., 2007) . In future studies definitions of DPD, DUP and DUI should be clear as these definitions determine the length of these periods. Thus, what measure is used to define onset of prodrome, psychosis or active treatment may be relevant for the subsequent findings of the study.
In our study we followed the patients from start of treatment to 5 years after this. However, DUI was determined retrospectively resulting in a weak test of a causal relationship between DUI and brain structure or outcome.
Conclusion
We hypothesized that through a shared association with outcome DUI would be associated with (change in) brain volume. However, although associations of baseline and 5-year follow-up symptom scores with both DUI as well as cerebral volume (change) were identified in first-episode patients, no associations were found between DUI and brain volume (change). Therefore, it seems that brain volume at illness onset and excessive tissue loss over time during the first years of the illness and DUI explain a different part of the variation in symptomatic and functional outcome.
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